Skip to main content
Top
Published in: Diabetologia 12/2005

01-12-2005 | Short Communication

Selective loss of glucose-induced amplification of insulin secretion in mouse pancreatic islets pretreated with sulfonylurea in the absence of fuels

Authors: K. A. Urban, U. Panten

Published in: Diabetologia | Issue 12/2005

Login to get access

Abstract

Aims/hypothesis

The beta cell metabolism of glucose, and some other fuels, initiates insulin secretion by closure of ATP-sensitive K+ channels and amplifies the secretory response via unknown metabolic intermediates. The aim of this study was to further characterise the mechanism responsible for the metabolic amplification of insulin secretion.

Materials and methods

Pancreatic islets were isolated from albino mice by collagenase digestion. Insulin secretion in perifused islets was determined by ELISA. Bioluminometry was used to determine the ATP and ADP content of the incubated islets.

Results

After perifusing islets for 60 min with 2.7 μmol/l glipizide (closing all ATP-sensitive K+ channels) in the absence of any fuel, perifusion with a test medium containing 2.7 μmol/l glipizide plus 30 mmol/l glucose did not enhance insulin secretion. However, test media supplemented with 2.7 μmol/l glipizide plus either 10 mmol/l α-ketoisocaproate or 10 mmol/l 2-aminobicyclo[2,2,1]heptane-2-carboxylic acid amplified the glipizide-induced insulin secretion. In pancreatic islets preincubated for 60 min with 2.7 μmol/l glipizide in the absence of any fuel, 40 min incubations in the presence of 2.7 μmol/l glipizide plus 30 mmol/l glucose or plus 10 mmol/l α-ketoisocaproate produced an increase in the ATP content, no change in the ADP content and a rather small increase in the ATP:ADP ratio. The corresponding effects of glucose and α-ketoisocaproate were similar.

Conclusions/interpretation

These results suggest that metabolic amplification of fuel-induced insulin secretion is not mediated by changes in the beta cell content of ATP and ADP, but might be due to export of citrate cycle intermediates to the beta cell cytosol.
Literature
1.
go back to reference Henquin J-C (2000) Perspectives in diabetes. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49:1751–1760PubMedCrossRef Henquin J-C (2000) Perspectives in diabetes. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49:1751–1760PubMedCrossRef
2.
go back to reference Wollheim CB (2000) Beta-cell mitochondria in the regulation of insulin secretion: a new culprit in type II diabetes. Diabetologia 43:265–277CrossRefPubMed Wollheim CB (2000) Beta-cell mitochondria in the regulation of insulin secretion: a new culprit in type II diabetes. Diabetologia 43:265–277CrossRefPubMed
3.
go back to reference MacDonald MJ, Fahien LA, Brown LJ, Hasan NM, Buss JD, Kendrick MA (2005) Perspective: emerging evidence for signaling roles of mitochondrial anaplerotic products in insulin secretion. Am J Physiol Endocrinol Metabol 288:E1–E15CrossRef MacDonald MJ, Fahien LA, Brown LJ, Hasan NM, Buss JD, Kendrick MA (2005) Perspective: emerging evidence for signaling roles of mitochondrial anaplerotic products in insulin secretion. Am J Physiol Endocrinol Metabol 288:E1–E15CrossRef
4.
go back to reference Yaney GC, Corkey BE (2003) Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia 46:1297–1312CrossRefPubMed Yaney GC, Corkey BE (2003) Fatty acid metabolism and insulin secretion in pancreatic beta cells. Diabetologia 46:1297–1312CrossRefPubMed
5.
go back to reference Roduit R, Nolan C, Alarcon C et al (2004) A role for the malonyl-CoA/long-chain acyl-CoA pathway of lipid signaling in the regulation of insulin secretion in response to both fuel and nonfuel stimuli. Diabetes 53:1007–1019PubMedCrossRef Roduit R, Nolan C, Alarcon C et al (2004) A role for the malonyl-CoA/long-chain acyl-CoA pathway of lipid signaling in the regulation of insulin secretion in response to both fuel and nonfuel stimuli. Diabetes 53:1007–1019PubMedCrossRef
6.
go back to reference Panten U, Burgfeld J, Goerke F et al (1989) Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets. Biochem Pharmacol 38:1217–1229CrossRefPubMed Panten U, Burgfeld J, Goerke F et al (1989) Control of insulin secretion by sulfonylureas, meglitinide and diazoxide in relation to their binding to the sulfonylurea receptor in pancreatic islets. Biochem Pharmacol 38:1217–1229CrossRefPubMed
7.
go back to reference Detimary P, Gilon P, Henquin J-C (1998) Interplay between cytoplasmic Ca2+ and the ATP/ADP ratio: a feedback control mechanism in mouse pancreatic islets. Biochem J 333:269–274PubMed Detimary P, Gilon P, Henquin J-C (1998) Interplay between cytoplasmic Ca2+ and the ATP/ADP ratio: a feedback control mechanism in mouse pancreatic islets. Biochem J 333:269–274PubMed
8.
go back to reference Heissig H, Urban KA, Hastedt K, Zünkler BJ, Panten U (2005) Mechanism of the insulin-releasing action of α-ketoisocaproate and related α-keto acid anions. Mol Pharmacol 68:1097–1105CrossRefPubMed Heissig H, Urban KA, Hastedt K, Zünkler BJ, Panten U (2005) Mechanism of the insulin-releasing action of α-ketoisocaproate and related α-keto acid anions. Mol Pharmacol 68:1097–1105CrossRefPubMed
9.
go back to reference Liu Y-J, Cheng H, Drought H, MacDonald MJ, Sharp GWG, Straub SG (2003) Activation of the KATP channel-independent signaling pathway by the nonhydrolyzable analog of leucine, BCH. Am J Physiol Endocrinol Metab 285:E380–E389 Liu Y-J, Cheng H, Drought H, MacDonald MJ, Sharp GWG, Straub SG (2003) Activation of the KATP channel-independent signaling pathway by the nonhydrolyzable analog of leucine, BCH. Am J Physiol Endocrinol Metab 285:E380–E389
10.
go back to reference Elmi A, Idahl L-A, Sehlin J (2000) Relationships between the Na+/K+ pump and ATP and ADP content in mouse pancreatic islets: effects of meglitinide and glibenclamide. Br J Pharmacol 131:1700–1706CrossRefPubMed Elmi A, Idahl L-A, Sehlin J (2000) Relationships between the Na+/K+ pump and ATP and ADP content in mouse pancreatic islets: effects of meglitinide and glibenclamide. Br J Pharmacol 131:1700–1706CrossRefPubMed
11.
go back to reference White CW, Rashed HM, Patel TB (1988) Sulfonylureas inhibit metabolic flux through rat liver pyruvate carboxylase reaction. J Pharmacol Exp Ther 246:971–974PubMed White CW, Rashed HM, Patel TB (1988) Sulfonylureas inhibit metabolic flux through rat liver pyruvate carboxylase reaction. J Pharmacol Exp Ther 246:971–974PubMed
12.
go back to reference Curi R, Carpinelli AR, Malaisse WJ (1991) Hexose metabolism in pancreatic islets: pyruvate carboxylase activity. Biochimie 73:583–586CrossRefPubMed Curi R, Carpinelli AR, Malaisse WJ (1991) Hexose metabolism in pancreatic islets: pyruvate carboxylase activity. Biochimie 73:583–586CrossRefPubMed
Metadata
Title
Selective loss of glucose-induced amplification of insulin secretion in mouse pancreatic islets pretreated with sulfonylurea in the absence of fuels
Authors
K. A. Urban
U. Panten
Publication date
01-12-2005
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 12/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-005-0030-5

Other articles of this Issue 12/2005

Diabetologia 12/2005 Go to the issue

EASD News Section

G.B. Morgagni Prizes 2006

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.